Northwest Biotherapeutics faces uncertain future amid cash woes
This article was originally published in Scrip
The survival of Northwest Biotherapeutics is in doubt after the company revealed that it has a severe shortage of cash. As of August 19th, it had cash of $1.1 million which will support its operations until the end of September. By midday, the news sent US company's shares down by 56% to 75 cents each.